Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crawford Nomination Clears OIG Hurdle To Face Committee Vote, Plan B Hold

This article was originally published in The Tan Sheet

Executive Summary

The conclusion of the HHS Inspector General's investigation into allegations against FDA Commissioner nominee Lester Crawford likely will bring the agency's delay of the Plan B emergency contraceptive switch application back into the foreground

You may also be interested in...



Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA

National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner

Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA

National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner

Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA

National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS098298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel